WASHINGTON, DC (August 6, 2020) — Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain and are working with policymakers to add to our significant manufacturing presence in the United States. The generic industry already makes tens of billions of doses of safe, effective and affordable medicines here in America each year and drafted recommendations to increase that production capacity – “A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain” – that we are discussing with the Administration and Capitol Hill.
AAM Interim CEO Jeff Francer stated, “The pharmaceutical supply chain has demonstrated its resilience during the pandemic by responding to unprecedented demand with strategies that ensured uninterrupted access to essential medicines for millions of patients. Without addressing the undervaluation of generic and biosimilar medicines in the U.S. with sustainable market supply plans, we simply cannot secure the domestic market and supply chain with scale and sustainability.”
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.